Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-07-21), the Forward Annual Dividend Yield of Venus Remedies is 0.59%.
As of today (2026-07-21), the Trailing Annual Dividend Yield of Venus Remedies is 0.00%.
NSE:VENUSREM's Forward Dividend Yield % is ranked worse than 81.41% of 511
companies
in the Drug Manufacturers industry
Industry Median: 2.03
vs NSE:VENUSREM: 0.59
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Venus Remedies was 14.50% per year. The lowest was -9.10% per year. And the median was 0.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Venus Remedies Forward Dividend Yield % Related Terms
NSE:VENUSREM vs ZTS, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Remedies Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Venus Remedies's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.59% mean?
Venus Remedies (NSE:VENUSREM) has a Forward Dividend Yield % of 0.59% as of Jul. 21, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Venus Remedies and its competitors. According to the industry distribution chart, Venus Remedies ranks #416 out of 511 companies in the Drug Manufacturers industry, placing it in the top 81.4%.
Is Venus Remedies' Forward Dividend Yield % too high?
Venus Remedies' current Forward Dividend Yield % is 0.59%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.03. Venus Remedies' value of 0.59% is 70.9% below this industry median. Based on the distribution chart, Venus Remedies ranks #416 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Venus Remedies has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Venus Remedies ranks #416 out of 511 companies for Forward Dividend Yield %. This places Venus Remedies in the lower half of its industry. The industry median Forward Dividend Yield % is 2.03. Venus Remedies' value of 0.59% is 70.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.03, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Remedies's current Forward Dividend Yield % of 0.59% is 70.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Venus Remedies and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Remedies's current Forward Dividend Yield % is 0.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (NSE:VENUSREM) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹466.33, compared to a current price of ₹1,775.50 — trading 280.7% above its estimated fair value. The current Forward Dividend Yield % is 0.59% and 70.9% below the Drug Manufacturers industry median of 2.03. Venus Remedies' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Venus Remedies (NSE:VENUSREM), the current Forward Dividend Yield % is 0.59% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Remedies (NSE:VENUSREM) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued.
The current stock price of ₹1,775.50 is trading 280.7% above its estimated GF Value™ of ₹466.33.
GuruFocus considers Venus Remedies to be Significantly Overvalued.
Key valuation signals for NSE:VENUSREM:
Forward Dividend Yield %: 0.59%
GF Value™: ₹466.33 vs. price of ₹1,775.50 (280.7% above fair value)
Industry Position: 70.9% below the Drug Manufacturers median (#416 of 511)
No single metric tells the full story. See the NSE:VENUSREM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
58GF Score
Get the complete analysis for NSE:VENUSREM
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VENUSREM has been successfully added to your 
